DK1427403T3 - Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling - Google Patents

Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling

Info

Publication number
DK1427403T3
DK1427403T3 DK02777129T DK02777129T DK1427403T3 DK 1427403 T3 DK1427403 T3 DK 1427403T3 DK 02777129 T DK02777129 T DK 02777129T DK 02777129 T DK02777129 T DK 02777129T DK 1427403 T3 DK1427403 T3 DK 1427403T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
combination
radiation
head
Prior art date
Application number
DK02777129T
Other languages
Danish (da)
English (en)
Inventor
Bernd Groner
Bernd Hentsch
Peter A Herrlich
Pier Giuseppe Pelicci
Martin Goettlicher
Thorsten Heinzel
Winfried Stephan Wels
Saverio Minucci
Original Assignee
Topotarget Germany Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Germany Ag filed Critical Topotarget Germany Ag
Application granted granted Critical
Publication of DK1427403T3 publication Critical patent/DK1427403T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK02777129T 2001-09-18 2002-09-17 Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling DK1427403T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01121722A EP1293205A1 (en) 2001-09-18 2001-09-18 Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease

Publications (1)

Publication Number Publication Date
DK1427403T3 true DK1427403T3 (da) 2006-04-03

Family

ID=8178602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777129T DK1427403T3 (da) 2001-09-18 2002-09-17 Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling

Country Status (11)

Country Link
US (1) US20050038113A1 (https=)
EP (4) EP1293205A1 (https=)
JP (1) JP2005512961A (https=)
AT (1) ATE314063T1 (https=)
AU (1) AU2002338716B2 (https=)
CA (1) CA2460713A1 (https=)
CY (1) CY1105552T1 (https=)
DE (1) DE60208397T2 (https=)
DK (1) DK1427403T3 (https=)
ES (1) ES2252519T3 (https=)
WO (1) WO2003024442A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
CN102349927A (zh) * 2003-08-29 2012-02-15 Hdac默克研究有限责任公司 联合治疗癌症的方法
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP5156392B2 (ja) * 2005-02-03 2013-03-06 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤を用いる併用療法
US7869590B2 (en) * 2005-04-12 2011-01-11 Broadcom Corporation Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
ATE542527T1 (de) 2005-05-13 2012-02-15 Topotarget Uk Ltd Pharmazeutische formulierungen von hdac-hemmern
EA200800321A1 (ru) * 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US9186339B2 (en) * 2005-11-16 2015-11-17 Universidad Nacional Autonoma De Mexico Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer
RU2389484C2 (ru) * 2005-11-18 2010-05-20 Универсидад Насиональ Аутонома Де Мексико Применение модифицирующих транскриптом агентов и химиотерапии или радиотерапии против рака
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
DE102006022877B4 (de) * 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California Small molecule potentiator of hormonal therapy for breast cancer
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US8642809B2 (en) 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
WO2010064422A1 (ja) * 2008-12-02 2010-06-10 静岡県公立大学法人 ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
KR101733189B1 (ko) * 2010-10-06 2017-05-08 (주)아모레퍼시픽 손톱 또는 발톱 성장 촉진용 조성물
CA2829263C (en) * 2011-03-21 2020-05-12 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
JP6551963B2 (ja) * 2014-05-14 2019-07-31 国立大学法人京都大学 巨核球前駆細胞の製造方法
MX388409B (es) 2014-06-12 2025-03-19 Cedars Sinai Medical Center Composiciones y metodos para tratar canceres.
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
CN117693363A (zh) * 2021-07-27 2024-03-12 东丽株式会社 用于癌的治疗和/或预防的药品

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
CA1339034C (en) * 1988-08-22 1997-04-01 Paul A. Tremblay Platinum complexes of single isomer neoalkyl acids
JPH0279969A (ja) * 1988-09-19 1990-03-20 Shigeyoshi Fujimoto 細胞障害性ｔ細胞誘導及び活性化の方法
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0632008B1 (en) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
US5672746A (en) * 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US6300373B1 (en) * 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6110955A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US6110970A (en) * 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
AU2337601A (en) * 1999-12-23 2001-07-09 Ontario Cancer Institute, The Inhibition of gsk-3beta
EP1170008A1 (en) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors

Also Published As

Publication number Publication date
WO2003024442A2 (en) 2003-03-27
EP1602371A2 (en) 2005-12-07
WO2003024442A3 (en) 2003-09-18
EP1602371A3 (en) 2006-11-15
EP1427403B1 (en) 2005-12-28
CY1105552T1 (el) 2010-07-28
AU2002338716B2 (en) 2007-08-16
DE60208397D1 (de) 2006-02-02
ATE314063T1 (de) 2006-01-15
DE60208397T2 (de) 2006-07-13
EP1427403A2 (en) 2004-06-16
EP1293205A1 (en) 2003-03-19
JP2005512961A (ja) 2005-05-12
ES2252519T3 (es) 2006-05-16
CA2460713A1 (en) 2003-03-27
EP1529527A3 (en) 2005-05-25
EP1427403B8 (en) 2006-03-22
EP1529527A2 (en) 2005-05-11
US20050038113A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DK1427403T3 (da) Valproinsyre til behandling af brystkræft, kolonkræft, hoved- og halskræft, lillecelle-lungecarcinom og kræft i blodceller i kombination med bestråling
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
DE50310516D1 (de) Fredericamycin-derivate
EA200501570A1 (ru) Новые гидроксаматы как лечебные средства
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
EA200400881A1 (ru) Азаарилпиперазины
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
HRP20040944B1 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
DE60229767D1 (de) Verwendung von laminarin in der behandlung von krebs
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
NO995838L (no) Nye heteroetynylenforbindelser og farmasoeytiske og kosmetiske preparater inneholdende de samme
ATE409039T1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
NO20064755L (no) Kombinasjonsterapi
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
DE60111622D1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
UA88884C2 (ru) Набор для приготовления фармацевтических композиций цис-оксоплатина, фармацевтическая композиция и ее применение при лечении рака
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
Keppler et al. Metallodrug Strategies in a Changing Environment of Anticancer Drug Development
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126
EA201991811A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ДОЗИРОВКА И СПОСОБ ЛЕЧЕНИЯ Ph+ ЛЕЙКЕМИЙ